Participación de los mineralocorticoides en la respuesta inflamatoria vascular asociada a la hipertensión

Palmer, 2000, Aldosterone and potassium secretion by the cortical collecting duct, Kidney Int, 57, 1324, 10.1046/j.1523-1755.2000.00970.x Palmer, 1999, Potassium secretion and the regulation of distal nephron K channels, Am J Physiol, 277, F821 Rossi, 2008, Primary aldosteronism: an up-date on screening, diagnosis and treatment, J Hypertens, 26, 1709, 10.1097/HJH.0b013e328306a0b8 Matsumura, 2006, Role of aldosterone in left ventricular hypertrophy in hypertension, Am J Hypertens, 19, 13, 10.1016/j.amjhyper.2005.05.013 Fallo, 2008, The metabolic syndrome in primary aldosteronism, Curr Diab Rep, 8, 42, 10.1007/s11892-008-0009-y Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001 Pitt, 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 348, 1309, 10.1056/NEJMoa030207 Brilla, 1990, Remodeling of the rat right and left ventricles in experimental hypertension, Circ Res, 67, 1355, 10.1161/01.RES.67.6.1355 Brilla, 1992, Reactive and reparative myocardial fibrosis in arterial hypertension in the rat, Cardiovasc Res, 26, 671, 10.1093/cvr/26.7.671 Rocha, 2002, The pathophysiology of aldosterone in the cardiovascular system, Ann N Y Acad Sci, 970, 89, 10.1111/j.1749-6632.2002.tb04415.x Rocha, 2002, Aldosterone induces a vascular inflammatory phenotype in the rat heart, Am J Physiol Heart Circ Physiol, 283, H1802, 10.1152/ajpheart.01096.2001 Rocha, 2001, Pathophysiological effects of aldosterone in cardiovascular tissues, Trends Endocrinol Metab, 12, 308, 10.1016/S1043-2760(01)00432-5 Rocha, 2000, Aldosterone: a mediator of myocardial necrosis and renal arteriopathy, Endocrinology, 141, 3871, 10.1210/endo.141.10.7711 Bautista, 2001, Is C-reactive protein an independent risk factor for essential hypertension?, J Hypertension, 19, 857, 10.1097/00004872-200105000-00004 Komatsu, 1997, Effects of chronic arterial hypertension on constitutive and induced intercellular adhesion molecule-1 expression in vivo, Hypertension, 29, 683, 10.1161/01.HYP.29.2.683 Peeters, 2001, Pro-inflammatory cytokines in patients with essential hypertension, Eur J Clin Invest, 31, 31, 10.1046/j.1365-2362.2001.00743.x Sheu, 2000, Plasma tumor necrosis factor alpha levels and insulin sensitivity in hypertensive subjects, Clin Exp Hypertens, 22, 595, 10.1081/CEH-100100094 González, 2000, Molecular plasticity of vascular wall during N(G)-nitro-L-arginine methyl ester-induced hypertension: modulation of proinflammatory signals, Hypertension, 36, 103, 10.1161/01.HYP.36.1.103 Luvara, 1998, Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall - Prevention by angiotensin II antagonism, Arterioscl Thromb Vasc Biol, 18, 1408, 10.1161/01.ATV.18.9.1408 Sanz-Rosa, 2005, Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-κB/IκB system, Am J Physiol Heart Circ Physiol, 288, H111, 10.1152/ajpheart.01061.2003 Tummala, 1999, Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis, Circulation, 100, 1223, 10.1161/01.CIR.100.11.1223 Sun, 2002, Aldosteroneinduced inflammation in the rat heart : role of oxidative stress, Am J Pathol, 161, 1773, 10.1016/S0002-9440(10)64454-9 Blasi, 2003, Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats, Kidney Int, 63, 1791, 10.1046/j.1523-1755.2003.00929.x Chomczynski, 1993, A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples, Biotechniques, 15, 532 Feldman, 2000, The role of tumor necrosis factor in the pathophysiology of heart failure, J Am Coll Cardiol, 35, 537, 10.1016/S0735-1097(99)00600-2 Kitamoto, 2004, Endothelial dysfunction and coronary atherosclerosis, Curr Drug Targets Cardiovasc Haematol Disord, 4, 13, 10.2174/1568006043481257 Newby, 2005, Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture, Physiol Rev, 85, 1, 10.1152/physrev.00048.2003 Nian, 2004, Inflammatory cytokines and postmyocardial infarction remodeling, Circulation Research, 94, 1543, 10.1161/01.RES.0000130526.20854.fa Ahima, 2000, Adipose tissue as an endocrine organ, Trends Endocrinol Metab, 11, 327, 10.1016/S1043-2760(00)00301-5 Burger, 2002, Cytokines, acute-phase proteins, and hormones: IL-1 and TNF-alpha production in contact-mediated activation of monocytes by T lymphocytes, Ann N Y Acad Sci, 966, 464, 10.1111/j.1749-6632.2002.tb04248.x Fujisawa, 1996, Activation of transcription factor NF-kappa B in human synovial cells in response to tumor necrosis factor alpha, Arthritis Rheumatism, 39, 197, 10.1002/art.1780390205 Collins, 1995, Transcriptional Regulation of Endothelial-Cell Adhesion Molecules - NF-κB and Cytokine-Inducible Enhancers, Faseb J, 9, 899, 10.1096/fasebj.9.10.7542214 Fujisawa, 1996, Activation of transcription factor NF-kappa B in human synovial cells in response to tumor necrosis factor alpha, Arthritis and Rheumatism, 39, 197, 10.1002/art.1780390205 Rovin, 1995, Activation of Nuclear Factor-kappa B Correlates with Mcp-1 Expression by Human Mesangial Cells, Kidney Int, 48, 1263, 10.1038/ki.1995.410 Ueda, 1994, NF-κB and Sp1 Regulate Transcription of the Human Mono-cyte Chemoattractant Protein-1 Gene, J Immunol, 153, 2052, 10.4049/jimmunol.153.5.2052 Muller, 2000, NF-κB inhibition ameliorates angiotensin II-induced inflammatory damage in rats, Hypertension, 35, 193, 10.1161/01.HYP.35.1.193 Fiebeler, 2001, Mineralocorticoid receptor affects AP-1 and nuclear factor-kappa B activation in angiotensin II-induced cardiac injury, Hypertension, 37, 787, 10.1161/01.HYP.37.2.787 Quaschning, 2001, Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension, Hypertension, 37, 801, 10.1161/01.HYP.37.2.801 Virdis, 2002, Spironolactone improves angiotensin-induced vascular changes and oxidative stress, Hypertension, 40, 504, 10.1161/01.HYP.0000034738.79310.06 Kuster, 2005, Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload, Circulation, 111, 420, 10.1161/01.CIR.0000153800.09920.40